Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: sim1 who wrote (1847)	8/9/2000 4:12:19 AM
From: nigel bates	of 4974

Aug. 8 /PRNewswire/ -- Rosetta Inpharmatics, Inc. (Nasdaq: RSTA - news) announced today that it has completed an initial public offering of 7,200,000 shares of its common stock at a price of $14 per share. The underwriters have a 30-day option to purchase up to an additional 1,080,000 shares at the same price per share. Gross proceeds to the company from the offering are approximately $100.8 million, before the exercise of the over-allotment and before deducting expenses for the offering and underwriting discounts and commissions. The public offering was lead managed by Lehman Brothers and co-managed by Lazard Freres & Co. LLC, Prudential Vector Healthcare Group, a unit of Prudential Securities, and Fidelity Capital Markets, a division of National Financial Services Corporation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next